Navigation Links
Alexza and Biovail Form Collaboration to Develop and Commercialize AZ-004 (Staccato(R) Loxapine) in North America
Date:2/10/2010

tion">the United States, and bipolar disorder, which affects approximately 5.7 million adults in the United States.  More than 90% of these patients will experience agitation in their lifetime.

Agitation generally escalates over time with patients initially feeling uncomfortable, tense and restless.  As the agitation intensifies, their behavior appears more noticeable to others as they become threatening and potentially violent, especially if the agitation is not treated.  While patients seek treatment at different points along this agitation continuum, those with the most severe symptoms generally require treatment with injectable drugs in emergency medical settings, and currently are thought to represent the agitation market.  Alexza, however, believes the therapeutic market for agitation is broader than only this limited perspective of patients in severe crisis — many more are in need of treatment for an agitation episode.

Alexza's primary market research indicates that approximately 50% of treated acute agitation episodes are treated in emergency settings.  Another approximately 35% of the treated agitation episodes suffered by schizophrenic and bipolar patients are treated in an inpatient setting (hospital and long-term residential settings), and approximately 15% are treated in a physician's office.

Alexza's market research studies with schizophrenia patient caregivers and bipolar patients indicate these patients currently experience an average of 11 to 12 episodes of acute agitation each year.

Agitation episodes are currently treated about 55% of the time with oral antipsychotics and about 45% of the time with intra-muscular, or IM, injections.  Oral medications work relatively slowly, but are easy to administer, painless and are less threatening to patients.  IM injections have a faster onset of action and a higher predictabili
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Alexza to Announce 2009 Second Quarter Financial Results and Update Its Clinical Pipeline Status on Wednesday, August 5, 2009
2. A Random Act of Kindness Changes a Familys Life Forever as Alexzander Prados Wish to Walk is Granted at Abilities Expo
3. Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002
4. Alexzas Corporate Presentation to be Webcast at the Piper Jaffray Fourth Annual Europe Conference
5. Alexzas Corporate Presentation to be Webcast at the Eighth Annual JMP Securities Research Conference
6. Alexza Reports 2008 Year-End Financial Results and Updates Clinical Pipeline Status
7. Alexzas Corporate Presentation to be Webcast at the Cowen & Company 29th Annual Health Care Conference
8. Alexza to Announce 2008 Financial Results and Update Its Clinical Pipeline on Tuesday, March 10, 2009
9. Alexza Pharmaceuticals Promotes Peter D. Noymer, PhD to Vice President, Product R&D
10. Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts
11. Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... According to a June 11, 2013 ABC News article, ... information surfaces about the negative effects of sun on ... one’s skin care routine, as the sun's rays ... , “I agree with the article's suggestions for the best ... of Epione Beverly Hills. “Apply a minimum of SPF 30, ...
(Date:6/17/2013)... Harvard Stem Cell Institute (HSCI) researchers have identified in ... to regulate embryonic stem cell self-renewal, beginning a creative ... , The gene, SALL4, gives stem cells their ability ... mature cells. Typically, cells only express SALL4 during embryonic ... cases of acute myeloid leukemia and 10 to 30 ...
(Date:6/17/2013)... childhood obesity, researchers at the Johns Hopkins Bloomberg ... are important. A systematic review of childhood obesity ... incorporate schools and focus on both diet and ... in children. The results of the study appear ... "In measuring the effectiveness of community-based programs that ...
(Date:6/17/2013)... pyrvinium pamoate inhibits aggressive forms of prostate cancer that ... conducted in an animal model. The results will be ... in San Francisco. , "Our novel prostate cancer drug ... lead author Jeremy Jones, PhD, assistant professor of molecular ... Duarte, CA. "Thus, it has the potential to treat ...
(Date:6/17/2013)... Reliable services of Link to Pay have been offered to ... can fix payment processing. , Schools and colleges have a ... fees from students and processing them may be a herculean ... cases, colleges and universities are looking for some smart solutions ... efficiently without any complications. , At the same time, parents ...
Breaking Medicine News(10 mins):Health News:Skin Care – Answers to Your Sunscreen Questions 2Health News:A new target for cancer drug development 2Health News:Community-based programs may help prevent childhood obesity 2Health News:New medication treats drug-resistant prostate cancer in the laboratory 2Health News:PayCanada Offers Link to Pay Services to its Customers 2
... Legislature,took an important step to help combat the rise ... according to the Michigan Dermatological Society,(MDS). , ... Frank Accavitti (D-Eastpointe), regulates,tanning salons by specifically requiring onsite ... tanning facilities listing potential health,consequences, and a signed informed ...
... company, explains the repercussions and risks of waiting to file for SSDI. ... ... the mistake of waiting too long to apply for Social Security disability ... people in the Social Security Disability Insurance (SSDI) process each ...
... With everyone mindful of,budgets and spending this holiday ... routine perfume or socks and to give gifts that ... too. Finding special gifts for loved ones with,asthma ... and allergy friendly(TM),Certification Program is helping holiday shoppers all ...
... Dec. 11 The following is a statement from Peter ... United States: , , The ... decline in underage drinking. The study,s authors point out that ... of alcohol by those under the legal drinking age. The ...
... Million Patient Pavilion , , CAMDEN, ... filled lobby as visitors gather in the coffee shop sipping lattes ... is the new patient Pavilion at Cooper University Hospital. Cooper celebrated ... a spectacular "Grand Lighting" of the Pavilion. , ...
... 11 Bioenergy Life Science -- The Ribose,Company ... Solutions, LLC, to market,Bioenergy D-Ribose(TM) in the Eastern ... to stimulate the synthesis of adenosine,triphosphate (ATP) -- ... "Collaborating with Xsto Solutions will ...
Cached Medicine News:Health News:Dermatologists Applaud Passage of Tanning Salon Regulation 2Health News:Time is Money When People Wait Too Long to Apply for Social Security Disability Benefits 2Health News:Time is Money When People Wait Too Long to Apply for Social Security Disability Benefits 3Health News:Time is Money When People Wait Too Long to Apply for Social Security Disability Benefits 4Health News:Spend Wisely This Holiday, Find Gifts That Are Good Fun and Good For You 2Health News:Spend Wisely This Holiday, Find Gifts That Are Good Fun and Good For You 3Health News:Cooper Opens Doors to New Era in Healthcare 2Health News:Cooper Opens Doors to New Era in Healthcare 3Health News:Bioenergy Life Science Retains Xsto Solutions to Market D-Ribose 2
(Date:6/17/2013)... TORONTO , June 17, 2013  Generex ... it entered into a securities purchase agreement with certain ... agreed to purchase in a private placement an aggregate ... Series E 9% Convertible Preferred Stock ("convertible preferred stock") ... 100% of the shares of its common stock issuable ...
(Date:6/17/2013)... -- Franciscan St. Francis Health Cancer Center today ... Indiana to use a new drug to treat ... Xofigo ®, a radiopharmaceutical used in patients with late-stage, ... was approved for use by the U.S. Food and Drug ... it may become castration-resistant, which has become resistant to medical ...
(Date:6/17/2013)... OSAKA, Japan , June 17, 2013 ... Takeda Pharmaceuticals U.S.A. , Inc. today ... KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and ... the United States (U.S.). These ... Administration (FDA) for the treatment of type 2 diabetes ...
Breaking Medicine Technology:Generex Announces $1,225,000 Capital Investment 2Generex Announces $1,225,000 Capital Investment 3Generex Announces $1,225,000 Capital Investment 4Generex Announces $1,225,000 Capital Investment 5New drug proving effective in attacking advanced prostate cancer 2Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 2Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 3Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 4Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 5Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 6Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 7Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 8Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 9
The Solar Radius Chair is a multi-functional and cost effective working environment. It can be used for simple and advanced urodynamic studies as well as for routine gynecology investigations....
... The Sonesta 6202 is the ... with our most popular accessories, ... for a myriad of exam ... (yet quiet) motors allow fast ...
... Model BR2 Bilirubin STAT-Analyzer® provides a rapid, ... in neonates. And because it's so compact ... for virtually any laboratory. The Model BR2 ... the only instrument that measures total and ...
... The Advanced® 2020 Multi-Sample Osmometer provides ... industrial, and research settings. These results ... freezing-point method, which determines total concentration. ... on-board data management, automated sample handling, ...
Medicine Products: